Skip to main content
Erschienen in:

11.04.2018 | Melanom | Leitthema

Läsionale Therapieoptionen beim maligen Melanom

verfasst von: F. Kiecker, G. Poch, K. Farmer

Erschienen in: Die Onkologie | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

In den letzten Jahren kam es bezüglich der systemischen Therapie des metastasierten malignen Melanoms durch die Einführung der Immuncheckpointinhibitoren und die Möglichkeit der zielgerichteten Therapie mit BRAF- und MEK-Inhibitoren zu einer revolutionären Entwicklung. Problematisch können allerdings die Nebenwirkungen der Therapien sein, und zudem ist man noch weit davon entfernt, allen Patienten ein Benefit mit diesen Therapien zu bescheren. Viele Melanompatienten entwickeln im metastasierten Stadium kutane, subkutane oder Lymphknotenmetastasen, die einer lokalen oder intraläsionalen Therapie zugänglich sind.

Material und Methode

Diese Arbeit basiert auf einer selektiven Literaturrecherche in der Datenbank PubMed zum Thema „Läsionale Therapie beim malignen Melanom“.

Ergebnisse und Schlussfolgerung

Auch im Bereich der läsionalen Therapie des metatasierten malignen Melanoms konnten Fortschritte mit neuen Therapiestrategien erreicht werden. Von besonderem Interesse sind hier die oftmals aktuell in klinischen Studien getesteten Kombinationstherapien, die unter Umständen die Möglichkeit der Resistenzüberwindung gegenüber einer Checkpointinhibitor-Monotherapie ermöglichen.
Literatur
1.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedPubMedCentralCrossRef Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Francken AB, Accortt NA, Shaw HM et al (2008) Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15(5):1476–1484PubMedCrossRef Francken AB, Accortt NA, Shaw HM et al (2008) Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15(5):1476–1484PubMedCrossRef
4.
Zurück zum Zitat Testori A, Chiarion Sileni V, Stanganelli I et al (2013) Surgical treatment of melanoma: a survey of Italian hospitals. Dermatology 226(Suppl. 1):28–31PubMedCrossRef Testori A, Chiarion Sileni V, Stanganelli I et al (2013) Surgical treatment of melanoma: a survey of Italian hospitals. Dermatology 226(Suppl. 1):28–31PubMedCrossRef
5.
Zurück zum Zitat Testori A, Intelisano A, Verrecchia F et al (2012) Alternative for the treatment of local advanced disease: electrochemotherapy, limb pefusion, limb infusion, intralesional Il2. What is the role? Dermatol Ther 25(5):443–451PubMedCrossRef Testori A, Intelisano A, Verrecchia F et al (2012) Alternative for the treatment of local advanced disease: electrochemotherapy, limb pefusion, limb infusion, intralesional Il2. What is the role? Dermatol Ther 25(5):443–451PubMedCrossRef
6.
Zurück zum Zitat Testori A, Faries MB, Thompson JF et al (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104:391–439PubMedCrossRef Testori A, Faries MB, Thompson JF et al (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104:391–439PubMedCrossRef
7.
Zurück zum Zitat Ebskov LB (1993) Major amputation for advanced melanoma: an epidemiological study. J Surg Oncol 52:89PubMedCrossRef Ebskov LB (1993) Major amputation for advanced melanoma: an epidemiological study. J Surg Oncol 52:89PubMedCrossRef
8.
Zurück zum Zitat Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632PubMedPubMedCentralCrossRef Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14(2):157–163PubMed Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14(2):157–163PubMed
10.
Zurück zum Zitat Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910PubMedCrossRef Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910PubMedCrossRef
11.
12.
Zurück zum Zitat Cavaliere R, Ciocatto EC, Giovanella BC et al (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20(9):1351–1381PubMedCrossRef Cavaliere R, Ciocatto EC, Giovanella BC et al (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20(9):1351–1381PubMedCrossRef
13.
Zurück zum Zitat Clark J, Grabs AJ, Parsons PG et al (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4(6):365–370PubMedCrossRef Clark J, Grabs AJ, Parsons PG et al (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4(6):365–370PubMedCrossRef
14.
Zurück zum Zitat Di Filippo F, Anza M, Rossi CR et al (1998) The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 14(3):215–223PubMedCrossRef Di Filippo F, Anza M, Rossi CR et al (1998) The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 14(3):215–223PubMedCrossRef
15.
Zurück zum Zitat Alexander HR Jr, Fraker DL, Bartlett DL et al (2010) Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 28(1):114–118PubMedCrossRef Alexander HR Jr, Fraker DL, Bartlett DL et al (2010) Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 28(1):114–118PubMedCrossRef
16.
Zurück zum Zitat Vrouenraets BC, Klaase JM, Kroon BB et al (1995) Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 130(1):43–47PubMedCrossRef Vrouenraets BC, Klaase JM, Kroon BB et al (1995) Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 130(1):43–47PubMedCrossRef
17.
Zurück zum Zitat Vrouenraets BC, Nieweg OE, Kroon BB (1996) Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83(10):1319–1322PubMedCrossRef Vrouenraets BC, Nieweg OE, Kroon BB (1996) Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83(10):1319–1322PubMedCrossRef
18.
Zurück zum Zitat Di Filippo F, Giacomini P, Rossi CR et al (2009) Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo (Brooklyn) 23(2):347–352 Di Filippo F, Giacomini P, Rossi CR et al (2009) Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo (Brooklyn) 23(2):347–352
19.
Zurück zum Zitat Eggermont AMM, de Wilt JHW, ten Hagen TLM (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4(7):429–437 (Review)PubMedCrossRef Eggermont AMM, de Wilt JHW, ten Hagen TLM (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4(7):429–437 (Review)PubMedCrossRef
20.
Zurück zum Zitat Hafstrom L, Rudenstam CM, Blomquist E et al (1991) Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 9(12):2091–2094PubMedCrossRef Hafstrom L, Rudenstam CM, Blomquist E et al (1991) Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 9(12):2091–2094PubMedCrossRef
21.
Zurück zum Zitat Aloia TA, Grubbs E, Onaitis M et al (2005) Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 140(11):1115–1120PubMedCrossRef Aloia TA, Grubbs E, Onaitis M et al (2005) Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 140(11):1115–1120PubMedCrossRef
22.
Zurück zum Zitat Noorda EM, Vrouenraets BC, Nieweg OE et al (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139(11):1237–1242PubMedCrossRef Noorda EM, Vrouenraets BC, Nieweg OE et al (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139(11):1237–1242PubMedCrossRef
23.
Zurück zum Zitat Grunhagen DJ, de Wilt JH, van Geel AN et al (2005) TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 31(9):1011–1019PubMedCrossRef Grunhagen DJ, de Wilt JH, van Geel AN et al (2005) TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 31(9):1011–1019PubMedCrossRef
24.
Zurück zum Zitat Hayes AJ, Neuhaus SJ, Clark Thomas MAJM (2007) Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advancedmelanoma and soft-tissue sarcoma. Ann Surg Oncol 14(1):230–238PubMedCrossRef Hayes AJ, Neuhaus SJ, Clark Thomas MAJM (2007) Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advancedmelanoma and soft-tissue sarcoma. Ann Surg Oncol 14(1):230–238PubMedCrossRef
25.
Zurück zum Zitat Thompson JF, Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16(2):227–233PubMedCrossRef Thompson JF, Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16(2):227–233PubMedCrossRef
26.
Zurück zum Zitat Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, deWilt JH, Eggermont AM (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240:939–947PubMedPubMedCentralCrossRef Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, deWilt JH, Eggermont AM (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240:939–947PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat de Wilt JH, ten Hagen TL, de Boeck G et al (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82(5):1000–1003PubMedPubMedCentralCrossRef de Wilt JH, ten Hagen TL, de Boeck G et al (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82(5):1000–1003PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Lejeune FJ, Eggermont AM (2007) Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 25(11):1449–1450 (author reply 1450–1451)PubMedCrossRef Lejeune FJ, Eggermont AM (2007) Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 25(11):1449–1450 (author reply 1450–1451)PubMedCrossRef
30.
Zurück zum Zitat Cornett WR, McCall LM, Petersen RP et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25):4196–4201PubMedCrossRef Cornett WR, McCall LM, Petersen RP et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25):4196–4201PubMedCrossRef
31.
Zurück zum Zitat Klaase JM, Kroon BB, van Geel AN et al (1993) Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80(9):1124–1126PubMedCrossRef Klaase JM, Kroon BB, van Geel AN et al (1993) Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80(9):1124–1126PubMedCrossRef
33.
Zurück zum Zitat Thompson JF, Waugh RC, Saw RPM, Kam PCA (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7:188–192 Thompson JF, Waugh RC, Saw RPM, Kam PCA (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7:188–192
34.
Zurück zum Zitat Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R, Ewing JH (1982) Tourniquet infusion versus hyperthermic perfusion. Cancer 49:850–858PubMedCrossRef Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R, Ewing JH (1982) Tourniquet infusion versus hyperthermic perfusion. Cancer 49:850–858PubMedCrossRef
35.
Zurück zum Zitat Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM (2001) Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 11:423–431PubMedCrossRef Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM (2001) Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 11:423–431PubMedCrossRef
36.
Zurück zum Zitat Kroon HM, Moncrieff M, Kam PC, Thompson JF (2008) Outcomes of isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15:3003–3013PubMedCrossRef Kroon HM, Moncrieff M, Kam PC, Thompson JF (2008) Outcomes of isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15:3003–3013PubMedCrossRef
37.
Zurück zum Zitat Kroon HM, Thompson JF, Hoekstra HJ (2009) Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs. Ned Tijdschr Geneeskd 153:508–514PubMed Kroon HM, Thompson JF, Hoekstra HJ (2009) Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs. Ned Tijdschr Geneeskd 153:508–514PubMed
39.
Zurück zum Zitat Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF (2008) Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity. Ann Surg Oncol 15:2749–2756PubMedCrossRef Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF (2008) Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity. Ann Surg Oncol 15:2749–2756PubMedCrossRef
40.
Zurück zum Zitat Beasley GM, Caudle A, Petersen RP et al (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208:706–715PubMedCrossRef Beasley GM, Caudle A, Petersen RP et al (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208:706–715PubMedCrossRef
41.
Zurück zum Zitat Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A (2001) Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 44:189–192PubMedPubMedCentral Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A (2001) Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 44:189–192PubMedPubMedCentral
42.
Zurück zum Zitat Hegazy MA, Kotb SZ, Sakr H et al (2007) Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 14:568–576PubMedCrossRef Hegazy MA, Kotb SZ, Sakr H et al (2007) Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 14:568–576PubMedCrossRef
43.
Zurück zum Zitat Ryan ER, Hill AD, Skehan SJ (2006) FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med 31:707–708PubMedCrossRef Ryan ER, Hill AD, Skehan SJ (2006) FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med 31:707–708PubMedCrossRef
44.
Zurück zum Zitat Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for intransit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195–2205PubMedCrossRef Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for intransit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195–2205PubMedCrossRef
45.
Zurück zum Zitat Lindner P, Doubrovsky A, Kam PCA, Thompson JF (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127–136PubMedCrossRef Lindner P, Doubrovsky A, Kam PCA, Thompson JF (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127–136PubMedCrossRef
46.
Zurück zum Zitat Barbour AP, Thomas J, Suffolk J et al (2009) Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 16:3463–3472PubMedCrossRef Barbour AP, Thomas J, Suffolk J et al (2009) Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 16:3463–3472PubMedCrossRef
47.
Zurück zum Zitat Huismans AM, Kroon HM, Kam PCA, Thompson JF (2011) Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 18(7):1877–1883PubMedCrossRef Huismans AM, Kroon HM, Kam PCA, Thompson JF (2011) Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 18(7):1877–1883PubMedCrossRef
48.
Zurück zum Zitat Brady MS, Brown K, Patel A, Fisher C, Marx W (2006) A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 13:1123–1129PubMedCrossRef Brady MS, Brown K, Patel A, Fisher C, Marx W (2006) A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 13:1123–1129PubMedCrossRef
49.
Zurück zum Zitat Kroon HM, Moncrieff M, Kam PC, Thompson JF (2009) Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 16:1184–1192PubMedCrossRef Kroon HM, Moncrieff M, Kam PC, Thompson JF (2009) Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 16:1184–1192PubMedCrossRef
50.
Zurück zum Zitat Kroon HM, Lin DY, Kam PC, Thompson JF (2009) Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma. Ann Surg 246:1008–1013CrossRef Kroon HM, Lin DY, Kam PC, Thompson JF (2009) Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma. Ann Surg 246:1008–1013CrossRef
51.
Zurück zum Zitat Kroon HM, Lin DY, Kam PC, Thompson JF (2009) Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 16:1193–1201PubMedCrossRef Kroon HM, Lin DY, Kam PC, Thompson JF (2009) Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 16:1193–1201PubMedCrossRef
52.
Zurück zum Zitat Beasley GM, McMahon N, Sanders G et al (2009) A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115:4766–4774PubMedCrossRef Beasley GM, McMahon N, Sanders G et al (2009) A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115:4766–4774PubMedCrossRef
53.
Zurück zum Zitat Beasley GM, Ross MI, Tyler DS (2008) Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 24:301–309PubMedCrossRef Beasley GM, Ross MI, Tyler DS (2008) Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 24:301–309PubMedCrossRef
54.
Zurück zum Zitat Dossett Lesly A, Ben-Shabat I, Olofsson Bagge R, Zager JS (2016) Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol 23(7):2330–2335PubMedCrossRef Dossett Lesly A, Ben-Shabat I, Olofsson Bagge R, Zager JS (2016) Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol 23(7):2330–2335PubMedCrossRef
55.
Zurück zum Zitat Berman B, Poochareon VN, Villa AM (2002) Novel dermatologic uses of the immune response modifier imiquimod 5 % cream. Skin Ther Lett 7(9):1–6 Berman B, Poochareon VN, Villa AM (2002) Novel dermatologic uses of the immune response modifier imiquimod 5 % cream. Skin Ther Lett 7(9):1–6
56.
Zurück zum Zitat Turza K, Dengel LT, Harris RC et al (2010) Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 37:94–98PubMedCrossRef Turza K, Dengel LT, Harris RC et al (2010) Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 37:94–98PubMedCrossRef
58.
Zurück zum Zitat Cohen MH, Jessup JM, Felix EL et al (1978) Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 41(6):2456–2463PubMedCrossRef Cohen MH, Jessup JM, Felix EL et al (1978) Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 41(6):2456–2463PubMedCrossRef
60.
Zurück zum Zitat Morton D, Eilber F, Malmgren R, Wood W (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158PubMed Morton D, Eilber F, Malmgren R, Wood W (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158PubMed
61.
Zurück zum Zitat Rosenberg S, Rapp H (1976) Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60(3):419–430PubMedCrossRef Rosenberg S, Rapp H (1976) Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60(3):419–430PubMedCrossRef
62.
Zurück zum Zitat Mastrangelo M, Bellet R, Berkelhammer J, Clark WJ (1975) Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36(4):1305–1308PubMedCrossRef Mastrangelo M, Bellet R, Berkelhammer J, Clark WJ (1975) Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36(4):1305–1308PubMedCrossRef
63.
Zurück zum Zitat Sparks F, Silverstein M, Hunt J, Haskell C, Pilch Y, Morton D (1973) Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289:827–830PubMedCrossRef Sparks F, Silverstein M, Hunt J, Haskell C, Pilch Y, Morton D (1973) Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289:827–830PubMedCrossRef
64.
Zurück zum Zitat Von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61(6):1071–1074CrossRef Von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61(6):1071–1074CrossRef
65.
Zurück zum Zitat Radny P, Caroli UM, Bauer J et al (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626PubMedPubMedCentralCrossRef Radny P, Caroli UM, Bauer J et al (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Pashenkov M, Goess G, Wagner C et al (2006) Phase II trial of a Toll-like receptor 9‑activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716–5724PubMedCrossRef Pashenkov M, Goess G, Wagner C et al (2006) Phase II trial of a Toll-like receptor 9‑activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716–5724PubMedCrossRef
67.
Zurück zum Zitat Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17(3):718–730PubMedCrossRef Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17(3):718–730PubMedCrossRef
68.
Zurück zum Zitat Andtbacka R, Kaufman H, Collichio F et al (2015) Talimogene laherparepvec improves durable responce rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2792PubMedCrossRef Andtbacka R, Kaufman H, Collichio F et al (2015) Talimogene laherparepvec improves durable responce rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2792PubMedCrossRef
70.
Zurück zum Zitat Toomey P, Kodumudi K, Weber A et al (2013) Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8:e68561PubMedPubMedCentralCrossRef Toomey P, Kodumudi K, Weber A et al (2013) Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8:e68561PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Sarnaik A, Crago G, Liu H et al (2014) Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol 32(15_suppl):9028–9028 Sarnaik A, Crago G, Liu H et al (2014) Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol 32(15_suppl):9028–9028
72.
Zurück zum Zitat Dees HC, Blair S, Harkins J et al (2012) Generation of an antitumor response and immunity using a small molecule drug (PV-10). Society for Immunotherapy of Cancer (SITC) Annual Meeting 2012. Abstract No. 1452582, 26.10.2012 Dees HC, Blair S, Harkins J et al (2012) Generation of an antitumor response and immunity using a small molecule drug (PV-10). Society for Immunotherapy of Cancer (SITC) Annual Meeting 2012. Abstract No. 1452582, 26.10.2012
73.
Zurück zum Zitat Bocci V (1961) Distribution and fate of rose bengal. Nature 189:584–585CrossRef Bocci V (1961) Distribution and fate of rose bengal. Nature 189:584–585CrossRef
74.
Zurück zum Zitat Meurman L (1960) On the distribution and kinetics of injected I131 rose bengal. An experimental study with special reference to the evaluation of liver function. Acta Med Scand S354:7–85 Meurman L (1960) On the distribution and kinetics of injected I131 rose bengal. An experimental study with special reference to the evaluation of liver function. Acta Med Scand S354:7–85
75.
Zurück zum Zitat Thompson JF, Agarwala SS, Smithers BM et al (2015) Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 22:2135–2142PubMedCrossRef Thompson JF, Agarwala SS, Smithers BM et al (2015) Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 22:2135–2142PubMedCrossRef
76.
Zurück zum Zitat Foote MC, Burmeister BH, Thomas J, Smithers BM (2010) A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy. Melanoma Res 20:48–51PubMedCrossRef Foote MC, Burmeister BH, Thomas J, Smithers BM (2010) A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy. Melanoma Res 20:48–51PubMedCrossRef
77.
Zurück zum Zitat Foote MC, Burmeister BH, Thomas J et al (2016) A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma. J Clin Oncol 34:e21072CrossRef Foote MC, Burmeister BH, Thomas J et al (2016) A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma. J Clin Oncol 34:e21072CrossRef
78.
Zurück zum Zitat Liu H, Innamarato PP, Kodumudi K et al (2016) Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 7:37893–37905PubMedPubMedCentral Liu H, Innamarato PP, Kodumudi K et al (2016) Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 7:37893–37905PubMedPubMedCentral
79.
Zurück zum Zitat Weber AM, Liu H, Kodumudi KN et al (2016) T cell mediated immunity after combination therapy with intralesional PV-10 and coinhibitory blockade in a melanoma model. AACR 107th Annual Meeting 2016, Abstract nr 4978. Weber AM, Liu H, Kodumudi KN et al (2016) T cell mediated immunity after combination therapy with intralesional PV-10 and coinhibitory blockade in a melanoma model. AACR 107th Annual Meeting 2016, Abstract nr 4978.
80.
Zurück zum Zitat Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM (2003) In vivo evolution of tumour cells after the generation of doublestrand DNA breaks. Br J Cancer 88:1763–1771PubMedPubMedCentralCrossRef Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM (2003) In vivo evolution of tumour cells after the generation of doublestrand DNA breaks. Br J Cancer 88:1763–1771PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Mir L (2006) Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl 4:38–44CrossRef Mir L (2006) Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl 4:38–44CrossRef
82.
Zurück zum Zitat Sadadcharam M, Soden DM, O’Sullivan GC (2008) Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 24:263–273PubMedCrossRef Sadadcharam M, Soden DM, O’Sullivan GC (2008) Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 24:263–273PubMedCrossRef
83.
Zurück zum Zitat Larkin JO, Collins CG, Aarons S et al (2007) Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg 245:469–479PubMedPubMedCentralCrossRef Larkin JO, Collins CG, Aarons S et al (2007) Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg 245:469–479PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Rudolf Z, Stabuc B, Cemazr M et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29:229–235 Rudolf Z, Stabuc B, Cemazr M et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29:229–235
85.
Zurück zum Zitat Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132:1353–1357PubMedCrossRef Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132:1353–1357PubMedCrossRef
86.
Zurück zum Zitat Heller R, Jaroszeski MJ, Reintgen DS et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83:148–157PubMedCrossRef Heller R, Jaroszeski MJ, Reintgen DS et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83:148–157PubMedCrossRef
87.
Zurück zum Zitat Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77:2336–2342PubMedPubMedCentralCrossRef Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77:2336–2342PubMedPubMedCentralCrossRef
88.
Zurück zum Zitat Campana LG, Mocellin S, Basso M et al (2009) Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 16:191–199PubMedCrossRef Campana LG, Mocellin S, Basso M et al (2009) Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 16:191–199PubMedCrossRef
90.
Zurück zum Zitat Testori A, Tosti G, Martinoli C et al (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23(6):651–661PubMedCrossRef Testori A, Tosti G, Martinoli C et al (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23(6):651–661PubMedCrossRef
91.
Zurück zum Zitat Mir L, Gehl J, Sersa G et al (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 4:14–25CrossRef Mir L, Gehl J, Sersa G et al (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 4:14–25CrossRef
92.
Zurück zum Zitat Byrne CM, Thompson JF (2006) Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 6:671–678PubMedCrossRef Byrne CM, Thompson JF (2006) Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 6:671–678PubMedCrossRef
93.
Zurück zum Zitat Campana LG, Testori A, Mozzillo N, Rossi CR (2014) Treatment of metastatic melanoma with electrochemotherapy. J Dermatol Sci 75:3–9CrossRef Campana LG, Testori A, Mozzillo N, Rossi CR (2014) Treatment of metastatic melanoma with electrochemotherapy. J Dermatol Sci 75:3–9CrossRef
94.
Zurück zum Zitat Pennacchioli E, Intelisano A, Verrecchia F et al (2013) Electrochemotherapy for treatment of locally advanced superficial cancer: results from a single institution. Ann Surg Oncol 20(1):S97–S97 Pennacchioli E, Intelisano A, Verrecchia F et al (2013) Electrochemotherapy for treatment of locally advanced superficial cancer: results from a single institution. Ann Surg Oncol 20(1):S97–S97
95.
Zurück zum Zitat Testori A, Rossi CR, Tosti G (2012) Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 24(2):155–161PubMedCrossRef Testori A, Rossi CR, Tosti G (2012) Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 24(2):155–161PubMedCrossRef
96.
Zurück zum Zitat Marty M, Gregor S, Garbay JR et al (2006) Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer 4(11):3–13CrossRef Marty M, Gregor S, Garbay JR et al (2006) Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer 4(11):3–13CrossRef
100.
Zurück zum Zitat Roux S, Bernat C, Al-Sakere B et al (2008) Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses. Cancer Immunol Immunother 57:1291–1300PubMedCrossRef Roux S, Bernat C, Al-Sakere B et al (2008) Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses. Cancer Immunol Immunother 57:1291–1300PubMedCrossRef
104.
Zurück zum Zitat Heppt MV, Eigentler TK, Kähler KC, Herbst RA, Göppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schäd SG, Schultz ES, Matheis F, Tietze JK, Berking C (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65(8):951–959. https://doi.org/10.1007/s00262-016-1856-z PubMedCrossRef Heppt MV, Eigentler TK, Kähler KC, Herbst RA, Göppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schäd SG, Schultz ES, Matheis F, Tietze JK, Berking C (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65(8):951–959. https://​doi.​org/​10.​1007/​s00262-016-1856-z PubMedCrossRef
Metadaten
Titel
Läsionale Therapieoptionen beim maligen Melanom
verfasst von
F. Kiecker
G. Poch
K. Farmer
Publikationsdatum
11.04.2018
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 6/2018
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-018-0371-6

Weitere Artikel der Ausgabe 6/2018

Der Onkologe 6/2018 Zur Ausgabe

Passend zum Thema

ANZEIGE

KEYNOTE-671-Studie: Zulassungserweiterung für Pembrolizumab zur perioperativen Therapie beim resezierbaren NSCLC

Ab sofort ist Pembrolizumab auch zur adjuvanten Monotherapie bei NSCLC mit hohem Rezidivrisiko nach vollständiger Resektion und Platin-basierter Chemo unabhängig von der PD-L1-Expression zugelassen.

ANZEIGE

Interaktiver mNSCLC-Patientenfall: Wie würden Sie entscheiden?

Verfolgen Sie in der interaktiven Kasuistik nach, für welchen Behandlungspfad sich Prof. Dr. Schütte mit seinem Team entschieden hat. Hätten Sie genau so gehandelt? Testen Sie Ihr Wissen und erfahren Sie mehr.

ANZEIGE

Fokus Immunonkologie – NSCLC

Content Hub

Die Einführung von Immun-Checkpoint-Inhibitoren markierte einen entscheidenden Fortschritt in der Behandlung von bestimmten Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer, NSCLC) und eröffnete seither neue Perspektiven und Chancen für Behandler und geeignete Patienten. Hier finden Sie fortlaufend aktuelle Informationen und relevante Beiträge zur Immunonkologie in dieser Indikation.

MSD Sharp & Dohme GmbH